US 12,435,377 B2
Cancers with loss of chromosome 16Q and/or low expression of metallothionein proteins
Steven Corsello, Boston, MA (US); Ryan Spangler, Cambridge, MA (US); Rohith Nagari, Cambridge, MA (US); and Todd Golub, Cambridge, MA (US)
Assigned to THE BROAD INSTITUTE, INC., Cambridge, MA (US); DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US); and INSTITUTO CARLOS SLIM DE LA SALUD, A.C, (MX)
Appl. No. 17/293,381
Filed by THE BROAD INSTITUTE, INC., Cambridge, MA (US); DANA-FARBER CANCER INSTITUTE, INC.; and INSTITUTO CARLOS SLIM DE LA SALUD, A.C., Mexico City (MX)
PCT Filed Nov. 13, 2019, PCT No. PCT/US2019/061120
§ 371(c)(1), (2) Date May 12, 2021,
PCT Pub. No. WO2020/102303, PCT Pub. Date May 22, 2020.
Claims priority of provisional application 62/767,478, filed on Nov. 14, 2018.
Prior Publication US 2022/0010383 A1, Jan. 13, 2022
Int. Cl. C12Q 1/6886 (2018.01); A61K 31/145 (2006.01); A61K 31/166 (2006.01); A61P 35/00 (2006.01)
CPC C12Q 1/6886 (2013.01) [A61K 31/145 (2013.01); A61K 31/166 (2013.01); A61P 35/00 (2018.01); C12Q 2600/106 (2013.01); C12Q 2600/154 (2013.01); C12Q 2600/158 (2013.01)] 16 Claims
 
1. A pharmaceutical composition for arresting the development of or relieving a cancer in a subject having arm-level loss of 16q, focal copy loss of 16q13 and/or low expression of a metallothionein gene and/or protein, as compared to a control, wherein the cancer is selected from the group consisting of a uterine cancer, an ovarian cancer, a gastroesophageal cancer and a lung cancer, the pharmaceutical composition comprising a therapeutically effective amount of disulfiram, diethyldithiocarbamate (DDC), Cu-DDC, elesclomol, or thiram and a pharmaceutically acceptable carrier.